Prognostic and Predictive Value of the 21-Gene Recurrence Score^® for Women with Node-Positive Breast Cancer Receiving Chemotherapy

Tyrosine Kinases as Targets for Cancer Therapy

Sunitinib versus Capecitabine for Patients with HER2-Negative Advanced Breast Cancer

SOLTI-0701 — A Double-Blind, Randomized Phase IIb Study of Capecitabine with or without Sorafenib in Advanced Breast Cancer

Double-Blind, Randomized Phase IIb Study of Paclitaxel with or without Sorafenib for Patients with HER2-Negative Advanced Breast Cancer

Analysis of the Incidence of Osteonecrosis of the Jaw and Surgical Complications with Neoadjuvant Therapy in Patients Receiving Bevacizumab

AVADO — Final Overall Survival Results of First-Line Docetaxel in Combination with Escalating Doses of Bevacizumab for HER2-Negative Metastatic Breast Cancer

RIBBON 2 — A Phase III Trial of Second-Line Bevacizumab in Combination with Chemotherapy for HER2-Negative Metastatic Breast Cancer

Loading Dose Schedule of Fulvestrant Combined with Anastrozole for the Treatment of Patients with Breast Cancer at First Relapse

High-Dose Fulvestrant for the Treatment of Postmenopausal Patients with Hormone Receptor-Positive Advanced Breast Cancer

Tumor Biomarker Changes After Presurgical Treatment of Patients with Breast Cancer with High-Dose Fulvestrant and Anastrozole

Phase II Study of Trastuzumab-DM1 (T-DM1) for Patients with Previously Treated HER2-Positive Metastatic Breast Cancer

NCCTG-N9831: Adjuvant Chemotherapy Alone or with Sequential or Concurrent Addition of 52 Weeks of Trastuzumab in HER2-Positive Breast Cancer

Efficacy of Trastuzumab-Based Regimens in Patients with HER2-Amplified Early-Stage Breast Cancer